ArticleEuropean journal of immunology2012
TSLP: from allergy to vaccine adjuvant.
Article in European journal of immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Trial
- Type III interferon exerts thymic stromal lymphopoietin in mediating adaptive antiviral immune response.Frontiers in immunology · 2023Review
- TWEAK mediates inflammation in experimental atopic dermatitis and psoriasis.Nature communications · 2017Article
- Review
- New directions in immunotherapy.Current allergy and asthma reports · 2013Review
- MicroRNA-375 regulation of thymic stromal lymphopoietin by diesel exhaust particles and ambient particulate matter in human bronchial epithelial cells.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- New routes for allergen immunotherapy.Human vaccines & immunotherapeutics · 2012Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The field of vaccine adjuvants has been an area of active research and development because of the need to improve the generation of protective immunity to a large number of pathogens, as well as in diseases such as cancer. Adjuvants can also help induce stronger immune responses with fewer injections, and consequently improve both the feasibility and success rate of large-scale population vaccine campaigns in developing countries. A current challenge is to identify vaccine adjuvants of various classes (cytokines, toll-like receptor ligands, etc.) with specific immune-modulating properties in order to tailor the immune response to certain pathological situations. In this issue, Van Roey et al. [Eur. J. Immunol. 2012. 42: 353-363] explore one of these challenges, namely to identify novel mucosal adjuvants. Van Roey et al. show that the pro-allergic cytokine thymic stromal lymphopoietin (TSLP) promotes a strong B-cell response with production of secretory IgA at mucosal sites. Here, we discuss the importance and limits of these findings within the broader field of vaccine adjuvants, and the potential development of TSLP as a mucosal and B-cell adjuvant in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.